MedImmune posts
FeedPosted May 23rd 2008 8:00AM by Laurie Pasternack (RSS feed)
Filed under: Newspapers, Magazines, Halliburton (HAL), Citigroup Inc. (C), Goldman Sachs Group (GS)
MAJOR PAPERS:
- In what may trump a GBP1.6B bid from a private-equity led consortium consisting of The Goldman Sachs Group Inc's (NYSE: GS) Goldman Sachs Capital Partners, Candover Investment (OTC: CDRIF), and Alpinvest, Expro International Group (OTC: EXPRF) said it received a GBP1.71B bid proposal from Halliburton Company (NYSE: HAL), the Wall Street Journal reported. Expro said the proposal "does not amount to a firm intention to make an offer and is subject to certain preconditions."
- The Wall Street Journal also reported that the oil industry and some U.S. lawmakers are looking to end long-standing bans on domestic drilling put in place to protect areas that are environmentally-sensitive, fueled by concerns about global energy.
- In an interview with the Financial Times, Citigroup Incorporated's (NYSE: C) former chairman and CEO Sandy Weill acknowledged that choosing Chuck Prince as his successor in 2003 turned out not to be the "right thing" for the company and was flawed. Instead of handing the job to Prince, Weill said the board should have fostered competition among the bank's top managers for the job.
OTHER PAPERS:
- According to the Washington Post, MedImmune, a unit of drug giant AstraZeneca Plc (NYSE: AZN),settled with Genentech Inc (NYSE: DNA) a lawsuit over a patented component of its best-selling drug Synagis, which is aimed at preventing respiratory infections in infants. No details of the settlement were provided.
Posted Jun 15th 2007 11:45AM by Brent Archer (RSS feed)
Filed under: Good news, Industry, Options, Technical Analysis, Gilead Sciences (GILD)
Gilead Sciences Inc. (NASDAQ:
GILD) opened at $81.24. So far today the stock has hit a low of $80.48 and a high of $82.17. As of 10:45, GILD is trading at 81.85, up 1.21 (1.5%).
The stock made a strong push in early spring to reach the low 80's and a one year high of 84.47 in May. The US Government has recently been ramping up efforts to fight against any future potential flu pandemic, including
awarding multi-million dollar contracts to
Sanofi-Aventis (NYSE:
SNY) and
MedImmune (NASDAQ:
MEDI) to increase their capacity to produce flu vaccines. GILD, maker of Tamiflu, could stand to benefit from such efforts as well. Recent technical indicators for GILD have been bullish but deteriorating, while
S&P gives the stock a 4 STARS (out of 5) buy rating.
For a bullish hedged play on this stock, I would consider an August
bull-put credit spread below the $70 range. GILD hasn't been below $70 since January and has shown support around $78 recently. This trade could be risky if the FDA finds trouble with one of GILD's drugs, but even if that happens, this position could be protected by the support around $70 combined with its 200 day moving average, which is currently at $71 and rising.
Brent Archer is an options analyst and writer at Investors Observer. Do you have any deadwood in your portfolio? Check out the 18 Warning Signs That Tell You When To Dump A Stock.
DISCLOSURE: Mr. Archer owns and/or controls diversified portfolios of long and short stock and option positions that may include holdings in companies he writes about. At publication time, Brent neither owns nor controls a position in GILD or MEDI. He does control a bullish hedged position in SNY.Posted May 25th 2007 3:30PM by Eric Buscemi (RSS feed)
Filed under: Earnings reports, Forecasts, Conventions and conferences, Annual meetings, Cisco Systems (CSCO), Dell (DELL), Exxon Mobil (XOM), Tiffany and Co (TIF), Costco Wholesale (COST), VeriFone Holdings (PAY), Polo Ralph Lauren'A' (RL)
.gif)
Here is a quick look at this upcoming holiday shortened week.
Monday May 28
- Markets closed for Memorial Day holiday.
- PDUFA date for MedImmune Inc's (NASDAQ: MEDI) sBLA for CAIV-T.
Tuesday May 29
Wednesday May 30
Thursday May 31
Friday June 1
Posted Apr 24th 2007 11:31AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Bad news, Sirius Satellite Radio (SIRI), Chevron Corp (CVX), Wendy's Intl (WEN), Symantec Corp (SYMC), Juniper Networks (JNPR)
MOST NOTEWORTHY: AstraZeneca plc (AZN), Aeroflex Inc (ARXX), Symantec Corp (SYMC), Chevron Corp (CVX) and Exxon Mobil Corp (XOM) were just some of today's noteworthy downgrades:
- HSBC downgraded shares of AstraZeneca plc (NYSE: AZN) to Neutral from Overweight as the firm believes investors will have to wait until 2009 for the company to start benefiting from its strategy.
- Aeroflexx Inc (NASDAQ: ARXX) was cut to Hold from Buy at Jefferies with a $14 target based on valuation.
- Thomas Weisel downgraded shares of Symantec Corp (NASDAQ: SYMC) to Market Weight from Overweight citing a lack of near-term catalysts and increased risk from transitions in its business model.
- Chevron Corp (NYSE: CVX) was removed from AG Edwards' Focus Portfolio. The firm believes Chevron offers less upside potential than other companies in the sector.
- Exxon Mobil (NYSE: XOM) was downgraded to Hold from Buy on valuation and its balanced risk/reward profile...
OTHER DOWNGRADES:
- Piper Jaffray cut Juniper Networks, Inc (NASDAQ: JNPR) to Market Perform from Outperform with a $20 target.
- Hecla Mining Co (NYSE: HL) was cut to Sector Underperformer from Sector Performer at CIBC based on valuation.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Apr 13th 2007 11:21AM by Kevin Shult (RSS feed)
Filed under: Analyst upgrades and downgrades, Bad news, Lockheed Martin (LMT), Limited Brands (LTD), Hunt(J.B.) Transport (JBHT)
MOST NOTEWORTHY: Some of today's noteworthy downgrades were Medimmune Inc (MEDI), J.B. Hunt (JBHT), Lockheed Martin (LMT), Komag (KOMG) and Victor Corp (VICR):
- Freidman Billings cut Medimmune inc (NASDAQ: MEDI) to Market Perform from Outperform on valuation. Prudential downgraded shares to Neutral from Overweight and recommended investors take profits in the company.
- J.B. Hunt Transport Services Inc (NASDAQ: JBHT) was downgraded to Peer Perform from Outperform at Bear Stearns citing valuation.
- Lockheed Martin (NYSE: LMT) was removed from Goldman Sachs Conviction Buy List and prefers L-3 Communication (LLL) over the large-cap aerospace/defense company.
- Komag Inc (NASDAQ: KOMG) was downgraded to Sell from Neutral at American Technology as they believe industry fundamentals have weakened and that the Seagate (STX) preannouncement will increase pricing pressure.
OTHER DOWNGRADES:
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Apr 4th 2007 10:58AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Bad news,
MOST NOTEWORTHY: First Data Corp (FDC), Pinnacle Entertainment, Inc (PNK), Cephalon, Inc (CEPH) and Verint Systems Inc (VRNT) were some of today's downgrades:
- UBS downgraded First Data Corp (NYSE: FDC) to Neutral from Buy following the acquisition by KKR.
- Pinnacle Entertainment (NYSE: PNK) was cut to Hold from Buy at Matrix USA, as the firm believes post-hurricane reconstruction efforts are leading to significant capital expenditures, which limits upside.
- Cephalon Inc (NASDAQ: CEPH) was removed from American Technology's Focus List with shares up 15% in three weeks as the approval of Nuvigil without a Black Box warning has passed.
- JP Morgan cut shares of Verint Systems (NASDAQ: VRNT) to Underweight from Neutral, citing risks and costs associated from the Witness Systems' (WITS) acquisition.
OTHER DOWNGRADES:
- Labor Ready, Inc (NYSE: LRW) was downgraded to Sell from Neutral at Goldman based on the slowdown in U.S. residential construction activity.
- JP Morgan downgraded Icagen, Inc (NASDAQ: ICGN) to Neutral from Overweight.
- Friedman Billings cut CompuDyne Corp (NASDAQ: CDCY) to Market Perform from Outperform following Q4 results.
Analyst summaries provided by
TheFlyOnTheWall.com (subscription required).
Posted Feb 9th 2007 4:15PM by Eric Buscemi (RSS feed)
Filed under: Earnings reports, Forecasts, Conventions and conferences, Annual meetings, Pfizer (PFE), Broadcom Corp'A' (BRCM)

Monday February 12
- Broadcom Corporation (NASDAQ: BRCM) to hold a 10:30am press conference from Barcelona on 3GSM.
- US and South Korea to hold Free-Trade Agreement talks from 2/11 to 2/14.
Tuesday February 13
- Extreme entertainment earnings:
- World Wrestling Entertainment (NYSE: WWE), conference call at 11am.
- Playboy Enterprises (NYSE: PLA), conference call at 11am. Note that Playboy was recently downgraded by RBC Capital Markets and Sanders Morris Harris. Sanders Morris said the company will either issue guidance below consensus expectations or none at all on the call.
- PDUFA date for Pfizer, Inc's (NYSE: PFE) Fesoterodine, a new drug candidate for the treatment of an overactive bladder.
Wednesday February 14
- Garmin Limited (NASDAQ: GRMN) to report Q4 earnings, conference call at 11am.
- MGM Mirage (NYSE: MGM) to report Q4 earnings, conference call at 11am.
- PDUFA date for Acambis plc's (OTC: ACAMY) ACAM-2000, a smallpox vaccine derived from Dryvax, a first-generation vaccine used during the global eradication program.
- PDUFA date for MedImmune Inc's (NASDAQ: MEDI) CAIV-T, an investigational intranasal, cold-adapted trivalent influenza vaccine.
Thursday February 15
- Biogen Idec Inc (NASDAQ: BIIB) to report Q4 earnings, conference call at 8:30am. On February 2, JP Morgan recommended buying Biogen before its quarterly report, saying the Tysbari uptake should be better than current expectations.
Friday February 16
- Jack in the Box Inc (NYSE: JBX) to hold annual shareholder meeting at 3pm.
Posted Feb 6th 2007 11:23AM by Kevin Shult (RSS feed)
Filed under: Before the bell, Analyst upgrades and downgrades, Bad news, Wendy's Intl (WEN)
MOST NOTEWORTHY: Wendy's International Inc (WEN) and NOVA Chemicals Corp (NCX) were today's most notable downgrades:
- Matrix USA downgraded shares of fast-food restaurant Wendy's International Inc (NYSE: WEN) to Sell from Hold to reflect the company's slowing revenues, increasing expenses and valuation.
- CIBC downgraded NOVA Chemicals Corp (NYSE: NCX) to Sector Underperformer from Sector Performer, lowering their target to $27.50 from $31 as they believe margins will be squeezed in 2008 once Middle Eastern supply begins to impact export markets.
OTHER DOWNGRADES:
- Following the company's lower guidance, UBS downgraded National Semiconductor Corp (NYSE: NSM) to Neutral from Buy with a $25 target, while Citigroup downgraded National Semi to Hold from Buy with a $27 target.
- Recent strength in Royal Caribbean Cruises Ltd (NYSE: RCL) forced Bank of America to remove it from their Top Pick list.
- Jefferies downgraded shares of Triad Hospitals Inc (NYSE: TRI) to Hold from Buy pending the buyout.
- JP Morgan downgraded shares of Altiris Inc (NASDAQ: ATRS) to Neutral from Outperform based on the Symantec (SYMC) acquisition.
- Thomas Weisel downgraded Medimmune Inc (NASDAQ: MEDI) to Market Perform from Outperform on valuation.
- Matrix USA downgraded Secure Computing Corp (NASDAQ: SCUR) to Sell from Buy on valuation.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Dec 20th 2006 11:55AM by Eric Buscemi (RSS feed)
Filed under: Analyst upgrades and downgrades, Ford Motor (F), Honeywell Intl (HON), Gilead Sciences (GILD)
MOST NOTEWORTHY: Symantec (NASDAQ:SYMC), Medimmune (NASDAQ:MEDI) and Ford (NYSE:F) were today's most notable upgrades:
- Goldman Sachs added Symantec and Medimmune to its Conviction Buy List. Goldman sees potential Q3 upside for Symantec and believes the company has an attractive valuation.
- Keybanc/McDonald upgraded Ford to Hold from Sell, saying it expects the rapid deterioration in earnings that occurred in 2006 to taper off as the company implements cost cuts and capacity rationalization actions.
OTHER UPGRADES:
- Gilead (NASDAQ: GILD) was upgraded to Above Average from Average at Caris & Co. as the firm believes the shares will rise on the potential NDA filing of AIR-CF2 in Q2 and its potential approval in early 2008.
- Honeywell (NYSE: HON) was upgraded to to Buy from Above Average at Caris & Co. on expected top-line growth driven by global macro trends.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).Posted Nov 7th 2006 11:27AM by Melly Alazraki (RSS feed)
Filed under: Analyst upgrades and downgrades, H and R Block (HRB)
MOST NOTEWORTHY: Swift Transportation (SWFT), JetBlue (JBLU) and Southwest (LUV) top today's list of upgrades.
- Following Director Moyer's offer to buy Swift Transportation, Inc. (NASDAQ:SWFT) for $29 a share, the company was upgraded to Market Perform from Underperform at Wachovia, to Peer Perform from Underperform at Bear Stearns and to Neutral from Sell at Bank of America.
- JetBlue Airways Corp. (NASDAQ:JBLU) was upgraded by Raymond James to Outperform from Market Perform following the October traffic report.
- Southwest Airlines Co. (NYSE:LUV) was upgraded to Outperform from Underperform at Credit Suisse based on valuation.
OTHER UPGRADES:
- Medimmune, Inc. (NASDAQ:MEDI) was upgraded to Outperform from Market Perform at Friedman, Billings Ramsey, citing Numax data and increased sales expectations for the drug.
- Finally, H&R Block, Inc. (NYSE:HRB) was upgraded to Buy from Sell at Soleil. The firm believes H&R Block's decision to explore strategic alternatives could lead to a possible sale of the whole company or certain parts of the company.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).